Hua Medicine (Shanghai) Dirección
Dirección controles de criterios 3/4
El CEO de Hua Medicine (Shanghai)'s es Li Chen , nombrado en Jun 2010, tiene una permanencia de 13.83 años. compensación anual total es CN¥22.63M, compuesta por 22.3% salario y 77.7% primas, incluidas acciones y opciones de la empresa. posee directamente un 3.97% de las acciones de la empresa, por valor de HK$61.75M. La antigüedad media del equipo directivo y de la junta directiva es de 4.2 años y 5.6 años, respectivamente.
Información clave
Li Chen
Chief Executive Officer (CEO)
CN¥22.6m
Compensación total
| Porcentaje del salario del CEO | 22.3% |
| Permanencia del CEO | 13.8yrs |
| Participación del CEO | 4.0% |
| Permanencia media de la dirección | 4.2yrs |
| Promedio de permanencia en la Junta Directiva | 5.6yrs |
Actualizaciones recientes de la dirección
Recent updates
Is Hua Medicine (Shanghai) (HKG:2552) Using Too Much Debt?
Nov 17
Investors Appear Satisfied With Hua Medicine (Shanghai) Ltd.'s (HKG:2552) Prospects
Aug 28We Think Hua Medicine (Shanghai) (HKG:2552) Can Afford To Drive Business Growth
Jan 06We're Interested To See How Hua Medicine (Shanghai) (HKG:2552) Uses Its Cash Hoard To Grow
Aug 02Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth
Apr 22Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth
Sep 23We're Not Worried About Hua Medicine (Shanghai)'s (HKG:2552) Cash Burn
Jun 24Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth
Mar 22Hua Medicine (Shanghai) Ltd.'s (HKG:2552) Profit Outlook
Feb 21Hua Medicine (Shanghai) (HKG:2552) Shareholders Booked A 21% Gain In The Last Year
Jan 25
Hua Medicine (Shanghai) (HKG:2552) Is In A Strong Position To Grow Its Business
Dec 21Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -CN¥211m |
| Sep 30 2023 | n/a | n/a | -CN¥200m |
| Jun 30 2023 | n/a | n/a | -CN¥189m |
| Mar 31 2023 | n/a | n/a | -CN¥196m |
| Dec 31 2022 | CN¥23m | CN¥5m | -CN¥204m |
| Sep 30 2022 | n/a | n/a | -CN¥234m |
| Jun 30 2022 | n/a | n/a | -CN¥265m |
| Mar 31 2022 | n/a | n/a | -CN¥295m |
| Dec 31 2021 | CN¥24m | CN¥5m | -CN¥326m |
| Sep 30 2021 | n/a | n/a | -CN¥355m |
| Jun 30 2021 | n/a | n/a | -CN¥385m |
| Mar 31 2021 | n/a | n/a | -CN¥389m |
| Dec 31 2020 | CN¥28m | CN¥5m | -CN¥393m |
| Sep 30 2020 | n/a | n/a | -CN¥378m |
| Jun 30 2020 | n/a | n/a | -CN¥363m |
| Mar 31 2020 | n/a | n/a | -CN¥394m |
| Dec 31 2019 | CN¥28m | CN¥4m | -CN¥425m |
| Sep 30 2019 | n/a | n/a | -CN¥1b |
| Jun 30 2019 | n/a | n/a | -CN¥2b |
| Mar 31 2019 | n/a | n/a | -CN¥3b |
| Dec 31 2018 | CN¥12m | CN¥2m | -CN¥4b |
| Sep 30 2018 | n/a | n/a | -CN¥3b |
| Jun 30 2018 | n/a | n/a | -CN¥2b |
| Mar 31 2018 | n/a | n/a | -CN¥440m |
| Dec 31 2017 | CN¥4m | CN¥3m | -CN¥273m |
Compensación vs. Mercado: La compensación total de Li($USD3.12M) está por encima de la media de empresas de tamaño similar en el mercado Hong Kong ($USD339.94K).
Compensación vs. Ingresos: La compensación de Li ha sido consistente con los resultados de la empresa en el último año.
CEO
Li Chen (60 yo)
13.8yrs
Permanencia
CN¥22,630,000
Compensación
Dr. Li Chen, Ph.D. is the Co-Founder of Hua Medicine (Shanghai) Ltd. and served as its Chief Scientific Officer until 2022 and served as its President until May 19, 2016 and has been its Chief Executive Of...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 13.8yrs | CN¥22.63m | 3.97% CN¥ 61.8m | |
| Executive VP | 1.3yrs | CN¥6.03m | 0.87% CN¥ 13.5m | |
| Vice President of Operation Department | 2.9yrs | sin datos | sin datos | |
| Director of Corporate Finance | no data | sin datos | sin datos | |
| CTO, VP of Chemical Manufacturing Control Department and Head of R&D in USA | 4.2yrs | sin datos | sin datos | |
| Chief Scientific Officer | 1.3yrs | sin datos | sin datos | |
| Head of IR | no data | sin datos | sin datos | |
| VP and Head of Commercial Strategy & Marketing | 5.7yrs | sin datos | sin datos | |
| Senior VP of Pharma Development & Chief Medical Officer – China and Executive Director | 6yrs | sin datos | sin datos | |
| VP of Quality Assurance & Chief Quality Officer | less than a year | sin datos | sin datos | |
| Company Secretary | 4.3yrs | sin datos | sin datos |
4.2yrs
Permanencia media
53yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de 2552 se considera experimentado (4.2 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 13.8yrs | CN¥22.63m | 3.97% CN¥ 61.8m | |
| Executive VP | 5.9yrs | CN¥6.03m | 0.87% CN¥ 13.5m | |
| Senior VP of Pharma Development & Chief Medical Officer – China and Executive Director | less than a year | sin datos | sin datos | |
| Non-Executive Chairman | 14yrs | sin datos | 0.015% CN¥ 238.6k | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Non-Executive Director | 5.6yrs | CN¥450.00k | 0.0024% CN¥ 38.1k | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Non-executive Director | 5.6yrs | CN¥540.00k | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Non-Executive Director | 1.3yrs | sin datos | sin datos | |
| Non-Executive Director | less than a year | sin datos | sin datos |
5.6yrs
Permanencia media
62yo
Promedio de edad
Junta con experiencia: La junta directiva de 2552 se considera experimentada (5.6 años de antigüedad promedio).